Dasabuvir: A non-nucleoside inhibitor of ns5b for the treatment of hepatitis c virus infection

Reviews on Recent Clinical Trials

Volumn 9, Issue 2, 2014, Pages 115-123

  Gentile, Ivan ^a   Buonomo, Antonio R ^a   Borgia, Guglielmo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

ABT 072; ABT 450; Dasabuvir; HCV; Interferon free; Ombitasvir; Pegylated interferon; Resistance; Ribavirin

Indexed keywords

DASABUVIR; PARITAPREVIR; PEGINTERFERON; ABT-333; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; SULFONAMIDE; URACIL; VIRUS PROTEIN;

AREA UNDER THE CURVE; ARTICLE; DERMATITIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EC50; FLATULENCE; HEPATITIS C; HUMAN; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); HEPATITIS C, CHRONIC;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPATITIS C, CHRONIC; HUMANS; SULFONAMIDES; URACIL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84924408414     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887109666140529222602     Document Type: Article

References (100)

1. [1] Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. [2] Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C Virus into 7 genotypes and 67 Subtypes: updated criteria and assignment web resource. Hepatology 2013; 1: 318-27.
3. [3] Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. Hepatology 1997; 26: 15S-20S.
4. [4] Sagnelli E, Pisaturo M, Stanzione M, et al. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C. Clin Gastroenterol Hepatol 2013; 11: 1174-80.
5. [5] Coppola N, Gentile I, Pasquale G, et al. Anti-HBc positivity was associated with histological cirrhosis in patients with chronic hepatitis C. Ann Hepatol 2014; 13: 20-6.
6. [6] Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 2012; 26: 401-12.
7. [7] Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic Hepatitis C. Hepatitis Monthly 2013; 13: e8352.
8. [8] Fortunato G, Calcagno G, Bresciamorra V, et al. Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 2008; 28: 141-52.
9. [9] Fortunato G, Castaldo G, Oriani G, et al. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001; 47: 1696-700.
10. [10] Gentile I, Meola M, Buonomo AR, et al. Human platelet antigen-3 genotype predicts platelet count in patients with HCV infection. In Vivo 2013; 27: 773-7.
11. [11] Sagnelli E, Coppola N, Marrocco C, et al. Hepatitis C virus superinfection in hepatitis B virus chronic carriers: a reciprocal viral interaction and a variable clinical course. J Clin Virol 2006; 35: 317-20.
12. [12] Sagnelli C, Uberti-Foppa C, Pasquale G, et al. Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection. Infection 2013; 41: 959-67.
13. [13] Coppola N, Zampino R, Bellini G, et al. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014; 12: 334-40.
14. [14] Gentile I, Buonomo AR, Zappulo E, Borgia G. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Infez Med 2014; 22: 11-8.
15. [15] Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
16. [16] Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005; 75: 522-7.
17. [17] Petruzziello A, Coppola N, Diodato AM, et al. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013; 56: 206-12.
18. [18] Guadagnino V, Stroffolini T, Caroleo B, et al. Hepatitis C virus infection in an endemic area of Southern Italy 14 years later: evidence for a vanishing infection. Dig Liver Dis 2013; 45: 403-7.
19. [19] Guadagnino V, Stroffolini T, Rapicetta M, et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997; 26: 1006-11.
20. [20] Gentile I, Di Flumeri G, Scarica S, et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva Urol Nefrol 2013; 65: 83-4.
21. [21] Carney K, Dhalla S, Aytaman A, Tenner CT, Francois F. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology 2013; 57: 2117-23.
22. [22] Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009; 46: 222-9.
23. [23] Coppola N, Pisapia R, Marrocco C, et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 2007; 40: 110-5.
24. [24] Gentile I, De Stefano A, Di Flumeri G, et al. Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report. In Vivo 2013; 27: 527-9.
25. [25] Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
26. [26] Gentile I, Viola C, Graf M, et al. A simple noninvasive score predicts gastroesophageal varices in patients with chronic viral hepatitis. J Clin Gastroenterol 2009; 43: 81-7.
27. [27] Ferrari SM, Fallahi P, Mancusi C, et al. HCV-related autoimmune disorders in HCV chronic infection. Clin Ter 2013; 164: e305-12.
28. [28] Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012; 44: 49-54.
29. [29] Zampino R CN, Cirillo G, Boemio A, et al. Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in thepathogenesis of liver steatosis in chronic hepatitis C. J Viral Hep 2013; 20: 517-23.
30. [30] Coppola N, Pascalis SD, Pisaturo M, et al. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells. J Clin Virol 2013; 58(4): 748-50.
31. [31] Fusco F, D'Anzeo G, Rossi A, et al. Erectile dysfunction in patients with chronic viral hepatitis: a systematic review of the literature. Expert Opin Pharmacother 2013; 14: 2533-44.
32. [32] Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol 2010; 52: 778.
33. [33] Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007; 13: 5648-53.
34. [34] Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004; 74: 406-13.
35. [35] Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-87.
36. [36] Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47: 484-91.
37. [37] Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
38. [38] Takahashi K, Nishida N, Kawabata H, Haga H, Chiba T. Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection. Intern Med 2012; 51: 2745-7.
39. [39] Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxo-butyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006; 49: 6074-86.
40. [40] Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70: 28-38.
41. [41] Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 3-16.
42. [42] Gentile I, Viola C, Borgia F, Castaldo G, Borgia G. Telaprevir: A promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009; 16: 1115-21.
43. [43] Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of Pegylated interferon alpha-2a and alpha-2b in patients with genotype 1 chronic hepatitis C: A meta-analysis. BMC Infect Dis 2012; 12: 1471-2334.
44. [44] Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335-74.
45. [45] Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus. Expert Opin Investig Drugs 2010; 19: 151-9.
46. [46] Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: A milestone in the treatment of chronic hepatitis C. World J Gastroenterol 2013; 19: 2793-8.
47. [47] Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-5.
48. [48] Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887-93.
49. [49] Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C infection. J Family Community Med 2013; 20: 35-40.
50. [50] Borgia G, Gentile I, Fortunato G, et al. Homocysteine levels and sustained virological response to pegylated-interferon alpha2b plus ribavirin therapy for chronic hepatitis C: A prospective study. Liver Int 2009; 29: 248-52.
51. [51] Distante S, Bjoro K, Hellum KB, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22: 269-75.
52. [52] Gentile I, Viola C, Paesano L, et al. Iron depletion before HCV antiviral therapy: a pilot, randomized, controlled trial. J Clin Apher 2009; 24: 190-6.
53. [53] Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17: 5184-90.
54. [54] Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J Gastroenterol 2012; 18: 800-5.
55. [55] Coppola N, Marrone A, Pisaturo M, et al. Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection. Eur J Clin Microbiol Infect Dis 2014; 33: 559-67.
56. [56] Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
57. [57] Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G. A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir. Curr Med Chem 2013; 20: 3733-42.
58. [58] Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56: S88-S100.
59. [59] Gentile I, Borgia F, Coppola N, Buonomo AR, Castaldo G, Borgia G. Daclatasvir: The First of a New Class of Drugs Targeted Against Hepatitis C Virus NS5A. Curr Med Chem 2014; 21: 1391-404.
60. [60] Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013; 58: 583-92.
61. [61] Gentile I, Borgia F, Zappulo E, et al. Efficacy and Safety of Sofosbuvir in Treatment of Chronic Hepatitis C: The Dawn of the a New Era. Rev Recent Clin Trials 2013; [Epub ahed of print].
62. [62] Gentile I, Buonomo AR, Borgia F, Castaldo G, Borgia G. Ledipasvir: a novel synthetic antiviral for the treatment of HCV Infection. Expert Opin Investig Drugs 2014; 23: 561-71.
63. [63] Gentile I, Buonomo AR, Borgia F, Zappulo E, Castaldo G, Borgia G. MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opin Investig Drugs 2014; 23: 719-28.
64. [64] Gentile I, Coppola N, Buonomo AR, Zappulo E, Borgia G. Investigational NS polymerase inhibitors and their use in treating HCV. Expert Opin Investig Drugs 2014. In press. DOI: 10.1517/13543784.2014.921680.
65. [65] Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
66. [66] Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
67. [67] FDA. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C. FDA press release; 2013 [updated 12/07/2013 cited 2014 17/01/2014]; Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377920.htm.
68. [68] Agency EM. European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C. [Press release] 2013 [updated 22 November 201301.02.2014]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_re lease/2013/11/WC500155469.pdf.
69. [69] Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature 2005; 436: 933-8.
70. [70] Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus: World J Gastroenterol 2007; 13(43): 5673-81.
71. [71] Pawlotsky JM. Hepatitis C virus population dynamics during infection. Curr Top Microbiol Immunol 2006; 299: 261-84.
72. [72] Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013; 28: 38-45.
73. [73] Soriano V, Vispo E, de Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 2013; 14: 1161-70.
74. [74] Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007; 8: 614-34.
75. [75] Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013; 22: 1107-21.
76. [76] Pockros PJ. Nucleoside/Nucleotide analogue polymerase inhibitors in development. Clin Liver Dis 2013; 17: 105-10.
77. [77] Maring C, Wagner R, Hutchinson D, et al. Preclinical potency, pharmacokinetic and ADME characterization of ABT-333, a novel non-Nucleoside HCV polymerase inhibitor. J Hepatol 2009; 50: S347-S.
78. [78] Pilot-Matias T, Koev G, Krishnan P, et al. In vitro combinatory effect of HCV NS3/4A Protease Inhibitor ABT-450, NS5A Inhibitor ABT-267, and non-nucleoside NS5B Polymerase Inhibitor ABT-333. J Hepatol 2012; 56: S338.
79. [79] Menon R, Cohen D, Nada A, et al. Pharmacokinetics, tolerability and effect of food on HCV polymerase inhibitor ABT-333 following single ascending doses in healthy adult volunteers. J Hepatol 2009; 50: S347-S8.
80. [80] Menon R, Cohen D, Nada A, et al. Pharmacokinetics, safety and tolerability of the HCV polymerase inhibitor ABT-333 following multiple ascending doses and effect of co-administration of ketoconazole in healthy subjects. J Hepatol 2009; 50: S348-S.
81. [81] Khatri A, Gaultier IA, Menon R, et al. Pharmacokinetics and Safety of Co-administered ABT-450 plus Ritonavir (ABT-450/r), ABT-267 and ABT-333 as a Single Dose in Subjects with Normal Hepatic Function and in Subjects with Mild, Moderate and Severe Hepatic Impairment. Hepatology 2012; 56: 555A-6A.
82. [82] Rodriguez-Torres M, Lawitz E, et al. Treatment-naive, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 2009; 50: 5.
83. [83] Poordad F, Lawitz E, DeJesus E, et al. ABT-072 or ABT-333 combined with pegylated interferon/ribavirin after 3-day monotherapy in HCV genotype 1 (GT1)-infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results. J Hepatol 2012; 56: S478-S.
84. [84] Gaultier I, Cohen DE, Bhathena A, et al. The effect of IL28B polymorphisms on virologic response to treatment with pegylated interferon alpha-2a and ribavirin (SOC) added to ABT-450/ritonavir (ABT-450/r), ABT-333, or ABT-072. J Hepatol 2011; 54: S523-S.
85. [85] Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
86. [86] Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370: 222-32.
87. [87] Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014; 10: 10.
88. [88] Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin. N Engl J Med 2014; 10: 10.
89. [89] Poordad F, Hezode C, Trinh R, et al. ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. N Engl J Med 2014; 11: 11.
90. [90] Baran RW, Xie W, Liu Y, Cohen DE, KL G. Health-Related Quality of Life (HRQoL), Health State, Function and Wellbeing of Chronic HCV Patients Treated with Interferon-Free, Oral DAA Regimens: Patient Reported Outcome (PRO) Results from the AVIATOR Study. Hepatology 2013; 58: 750A-1A.
91. [91] Cohen DE XW, Larsen L, Marincic C, et al. Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects with Ribavirin Dose Reductions. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 2013; Washington, DC.
92. [92] Sulkowski MS, Shiffman ML, Afdhal NH, et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139: 1602-11.
93. [93] Koev G, Mondal R, Beyer J, et al. Characterization of resistance mutations selected in vitro by the non-nucleoside HCV polymerase inhibitors ABT-333 and ABT-072. J Hepatol 2009; 50: S346-S7.
94. [94] Middleton T, He Y, Beyer J, et al. Resistance profile of ABT-333 and relationship to viral load decrease in patients treated in combination with peg-Interferon and ribavirin for 28 days. J Hepatol 2010; 52: S296-S7.
95. [95] Borgia G, Carleo MA, Gaeta GB, Gentile I. Hepatitis B in pregnancy. World J Gastroenterol 2012; 18: 4677-83.
96. [96] Gentile I, Zappulo E, Buonomo AR, Borgia G. Prevention of mother-to-child transmission of HBV and HCV. Expert Rev Anti Infect Ther 2014; 12(7): 775-82.
97. [97] Lawitz E, Hazan L, Gruener D, et al. GS-9669, a novel NS5B non-nucleotide site II inhibitor, demonstrates potent antiviral activity, favorable safety profile and potential for once-daily dosing. J Hepatol 2012; 56: S471-S.
98. [98] Sims K, Lemm J, Eley T, et al. A Randomized, Placebo-Controlled, Single Ascending Dose Study of BMS-791325, a Hepatitis C Virus NS5B Polymerase Inhibitor, in Genotype 1 Infection. Antimicrob Agents Chemother 2014; 14: 14.
99. [99] Reddy R, Rodriguez-Torres M, Gane E, et al. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 2007; 46: 862A-3A.
100. [100] Lawitz EJ, Rodriguez-Torres M, Denning J, et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear). J Viral Hepat 2013; 20: 699-707.